MedTrace Logo

EPOMI Study: ErythroPOietin in Myocardial Infarction

NCT00648089 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2011-01-31

No results posted yet for this study

Summary

EPOMI is a randomized, open-label, parallel phase II clinical study that will evaluate the effects of a single erythropoietin administration on infarct size and cardiac remodeling in patients with acute myocardial infarction. Eligible patients will be randomly assigned to receive conventional therapy and single infusion of 1000U/kg of epoetin beta or conventional therapy alone. Infarct size and cardiac remodeling parameters will be assessed by cardiac magnetic resonance imaging (MRI) within 3-7 days of the randomization and repeated 3 months later.

Conditions

Interventions

DRUG

EPO

Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI

Sponsors & Collaborators

  • Fédération Française de Cardiologie

    collaborator OTHER

  • Société Française de Cardiologie

    collaborator OTHER

  • University Hospital, Angers

    lead OTHER_GOV

Principal Investigators

  • Fabrice PRUNIER, MD, PhD · University Hospital, Angers

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00648089 on ClinicalTrials.gov